Nima Nabavizadeh, Associate Professor of Radiation Medicine at the Oregon Health and Science University, the supervising author of " Low Utilization of External Beam Radiation Therapy for Patients With Unresectable Hepatocellular Carcinoma: An Analysis of the United Network for Organ Sharing Database" and Dr. Jeffrey Olsen, Associate Professor of Radiation Oncology at the University of Colorado and section editor of our gastrointestinal section, co-leads a discussion along with our Editor-in-Chief Dr. SBRT, Versus or With Other Liver-Directed Therapiesĭr. Jeffrey Cao, Provincial Breast Tumour Team Lead for Alberta Health Services and Clinical Associate Professor at the University of Calgary, who supervised a new article in this month’s issue, Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study. TH in Women With Stage I HER2 Positive Breast Cancer, as well as Dr. Director of Breast Radiation Oncology at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and first author of a Red Journal paper from May 2022 called Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. Jennifer Bellon, Section Editor for breast cancers. Sara Alcorn, Associate Editor and Associate Professor of Radiation Oncology at the University of Minnesota, who first-authored this month’s Oncology Scan, Toxicity and Timing of Breast Radiotherapy with Overlapping Systemic Therapies and Dr. Radiotherapy for Breast Cancer in Combination With Novel Systemic TherapiesĮditor-in-Chief Dr. David Palma, Clinician Scientist II at the Ontario Institute for Cancer Research, Radiation Oncologist at the London Health Sciences Center, and Associate Professor at Western University, who was the supervising author on the 5-year update of the SABR-COMET trial, " Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET) – Extended Long-Term Outcomes." Matthias Guckenberger, Chairman and Professor of the Department of Radiation Oncology at the University Hospital Zurich and University of Zurich, discussing a new article from his European team, " Completeness of reporting oligometastatic disease characteristics in the literature and influence on oligometastatic disease classification using the ESTRO/EORTC nomenclature," and Dr. Salma Jabbour, Vice Chair of Clinical Research and Faculty Development and Clinical Chief in the Department of Radiation Oncology at the Rutgers Cancer Institute of New Jersey, hosts Dr. Oligometastasis - The Special Issue, Part 1ĭeputy Editor Dr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |